Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H19N3O6S.2H2O |
| Molecular Weight | 441.456 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)[C@H](N)C3=CC=CC=C3)C2=O)C(O)=O
InChI
InChIKey=KURFSUDYQUKEJZ-SBMYYUOMSA-N
InChI=1S/C18H19N3O6S.2H2O/c1-9(22)27-7-11-8-28-17-13(16(24)21(17)14(11)18(25)26)20-15(23)12(19)10-5-3-2-4-6-10;;/h2-6,12-13,17H,7-8,19H2,1H3,(H,20,23)(H,25,26);2*1H2/t12-,13-,17-;;/m1../s1
| Molecular Formula | C18H19N3O6S |
| Molecular Weight | 405.425 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | H2O |
| Molecular Weight | 18.0153 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Cephaloglycin, first oral cephalosporin, was introduced in 1965, but is no longer in common use. It is an orally absorbed derivative of cephalosporin C. Cephaloglycin binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. PBPs are enzymes involved in the terminal stages of assembling the bacterial cell wall and in reshaping the cell wall during growth and division. Inactivation of PBPs interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity. This results in the weakening of the bacterial cell wall and causes cell lysis.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
0.8 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4887297/ |
0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered: |
CEPHALOGLYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4887297/ |
0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered: |
CEPHALOGLYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4887297/ |
0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered: |
CEPHALOGLYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
75% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4887297/ |
0.5 g single, oral dose: 0.5 g route of administration: Oral experiment type: SINGLE co-administered: |
CEPHALOGLYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Protein engineering of penicillin acylase. | 2010-07 |
|
| Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project. | 2010 |
|
| Determination of cephalosporins in solid binary mixtures by polarized IR- and Raman spectroscopy. | 2008-09-10 |
|
| Treating critical illness: the importance of first doing no harm. | 2005-06 |
|
| Plasma glutathione peroxidase and its relationship to renal proximal tubule function. | 1998-11 |
|
| beta-Lactam drug allergens: fine structural recognition patterns of cephalosporin-reactive IgE antibodies. | 1996-07-01 |
|
| The renal mitochondrial toxicity of beta-lactam antibiotics: in vitro effects of cephaloglycin and imipenem. | 1990-11 |
|
| Drugs as allergens: an immunoassay for detecting IgE antibodies to cephalosporins. | 1990 |
|
| Oxidative and mitochondrial toxic effects of cephalosporin antibiotics in the kidney. A comparative study of cephaloridine and cephaloglycin. | 1989-03-01 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4385749
Each subject received a
single oral dose of each of the following: 250, 500,
and 1,000 mg of cephaloglycin after an overnight fast
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/697348
Curator's Comment: All strains of group A streptococci
(Streptococcus pyogenes) and Diplococcus pneumoniae were inhibited by 0.4
ug of cephaloglycin per ml. https://www.ncbi.nlm.nih.gov/pubmed/4385749
M. hyorhinis strains were susceptible to cephaloglycin (MIC = 4.1 ug/ml)
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:36:14 GMT 2025
by
admin
on
Mon Mar 31 17:36:14 GMT 2025
|
| Record UNII |
NE7R11LA95
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C65307
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY | |||
|
22202-75-1
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY | |||
|
166592
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY | |||
|
DTXSID20176751
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY | |||
|
NE7R11LA95
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200971
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY | |||
|
Cephaloglycin
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY | |||
|
DBSALT001839
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY | |||
|
m1064
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY | Merck Index | ||
|
D002507
Created by
admin on Mon Mar 31 17:36:14 GMT 2025 , Edited by admin on Mon Mar 31 17:36:14 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |